Arbutus Biopharma Corporation
ABUS
$2.80
$0.093.32%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 18.14M | 22.24M | 23.54M | 33.13M | 39.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.14M | 22.24M | 23.54M | 33.13M | 39.02M |
| Cost of Revenue | 73.70M | 79.09M | 78.97M | 84.22M | 84.41M |
| Gross Profit | -55.56M | -56.84M | -55.44M | -51.10M | -45.39M |
| SG&A Expenses | 22.48M | 21.62M | 19.27M | 18.49M | 17.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.18M | 100.71M | 98.25M | 102.72M | 102.24M |
| Operating Income | -78.03M | -78.47M | -74.71M | -69.59M | -63.22M |
| Income Before Tax | -72.85M | -75.47M | -72.93M | -70.03M | -65.01M |
| Income Tax Expenses | -- | 0.00 | 0.00 | 0.00 | 4.44M |
| Earnings from Continuing Operations | -72.85 | -75.47 | -72.93 | -70.03 | -69.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.85M | -75.47M | -72.93M | -70.03M | -69.46M |
| EBIT | -78.03M | -78.47M | -74.71M | -69.59M | -63.22M |
| EBITDA | -76.63M | -77.12M | -73.38M | -68.22M | -61.80M |
| EPS Basic | -0.44 | -0.47 | -0.46 | -0.45 | -0.46 |
| Normalized Basic EPS | -0.27 | -0.28 | -0.28 | -0.27 | -0.26 |
| EPS Diluted | -0.44 | -0.47 | -0.46 | -0.45 | -0.46 |
| Normalized Diluted EPS | -0.27 | -0.28 | -0.28 | -0.27 | -0.26 |
| Average Basic Shares Outstanding | 663.81M | 650.82M | 634.30M | 616.99M | 603.77M |
| Average Diluted Shares Outstanding | 663.81M | 650.82M | 634.30M | 616.99M | 603.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
